Labiana Health S.A. - Asset Resilience Ratio
Labiana Health S.A. (LAB) has an Asset Resilience Ratio of 0.00% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LAB current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Labiana Health S.A.'s Asset Resilience Ratio has changed over time. See LAB net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Labiana Health S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Labiana Health S.A. worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €800.25 | 0.0% |
| Total Liquid Assets | €800.25 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Labiana Health S.A. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Labiana Health S.A. Industry Peers by Asset Resilience Ratio
Compare Labiana Health S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Labiana Health S.A. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Labiana Health S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €800.25 ≈ $935.58 |
€52.00 Million ≈ $60.80 Million |
-0.02pp |
| 2023-12-31 | 0.02% | €13.94K ≈ $16.30K |
€59.12 Million ≈ $69.12 Million |
-4.16pp |
| 2022-12-31 | 4.19% | €2.54 Million ≈ $2.97 Million |
€60.78 Million ≈ $71.06 Million |
+4.17pp |
| 2021-12-31 | 0.02% | €11.45K ≈ $13.38K |
€68.37 Million ≈ $79.93 Million |
-- |
About Labiana Health S.A.
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms,… Read more